Non-diabetic adults over 50 who took GLP-1 drugs like semaglutide had a 39% lower rate of age-related macular degeneration compared to those on other weight loss medications.
53% lower risk of dry AMDGLP-1 users had roughly half the rate of nonexudative AMD compared to those on other weight loss drugs (HR 0.47)
What the researchers found
In a propensity-matched retrospective study of 20,959 patients per group, GLP-1 receptor agonists were associated with a significantly lower hazard of nonexudative AMD (HR 0.47, 95% CI 0.28–0.78) and any AMD (HR 0.61, 95% CI 0.43–0.85) compared to other weight loss pharmacotherapies.
The difference for exudative (wet) AMD alone was not statistically significant (HR 0.63, 95% CI 0.30–1.32). Importantly, BMI and hemoglobin A1c trajectories were similar between the two groups over follow-up, suggesting the protective association is not simply driven by greater weight loss or metabolic improvement.
Why it matters
Age-related macular degeneration is the leading cause of irreversible vision loss in older adults, and treatment options for the dry form are extremely limited. If GLP-1 drugs genuinely reduce AMD risk through mechanisms beyond weight loss — possibly through anti-inflammatory or neuroprotective effects — it could represent an unexpected bonus for the millions already taking these medications and a new avenue for AMD prevention research.
How the study worked
This was a retrospective cohort study using de-identified data from the TriNetX Research Network (June 2021–October 2025). Researchers identified non-diabetic adults aged 50+ prescribed either GLP-1 receptor agonists or other weight loss drugs, requiring at least two prescriptions six months apart. After 1:1 propensity score matching on demographics, AMD risk factors, and access to eye care, 20,959 patients remained in each cohort. Outcomes were analyzed using Cox proportional hazards models.
What this study cannot tell us
This is a retrospective observational study, so it cannot prove causation — only association. The TriNetX database relies on diagnostic codes, which may miss early or undiagnosed AMD. The study excluded diabetic patients, so findings may not apply to those with diabetes. Follow-up duration was limited, and exudative AMD results were not statistically significant, possibly due to its lower incidence. There may be unmeasured confounders despite propensity matching.
How to read the evidence
This is a large retrospective cohort study with propensity score matching, which provides moderate evidence. While the sample size is strong and matching was thorough, it cannot establish causation, and unmeasured confounders may exist.
When this study was published
Published in 2025 with data through October 2025, this is a very recent study reflecting the latest real-world evidence on GLP-1 drugs and eye health.
The bigger picture
GLP-1 receptor agonists continue to show surprising benefits beyond weight loss and diabetes — from cardiovascular protection to kidney disease to now potentially eye health. This study adds to the growing picture of GLP-1 drugs as broadly protective, though the mechanisms in the retina remain unclear. Researchers suspect anti-inflammatory properties may be at play, since chronic inflammation is a key driver of AMD.
Questions still open
- What biological mechanism might explain GLP-1 drugs' protective effect on the retina independent of weight loss?
- Would these findings hold up in a prospective randomized trial specifically designed to measure eye outcomes?
- Does the duration of GLP-1 use affect the degree of AMD risk reduction?
Common questions
Can GLP-1 drugs prevent age-related macular degeneration?
Why were only non-diabetic patients included in this study?
Read the original research
Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapies.
Ophthalmology. Retina
Citation
Myers, Walter K; Heath, Garrett; Rohrer, Bärbel. (2025). Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapies.. Ophthalmology. Retina. https://doi.org/10.1016/j.oret.2025.12.016